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Abstract
Background: Traumatic brain injury (TBI) results in important neurological impairments which occur through a
cascade of deleterious physiological events over time. There are currently no effective treatments to prevent
these consequences. TBI is followed not only by an inflammatory response but also by a profound reorganization
of the GABAergic system and a dysregulation of translocator protein 18 kDa (TSPO). Etifoxine is an anxiolytic
compound that belongs to the benzoxazine family. It potentiates GABAergic neurotransmission, either through a
positive allosteric effect or indirectly, involving the activation of TSPO that leads to an increase in neurosteroids
synthesis. In several models of peripheral nerve injury, etifoxine has been demonstrated to display potent
regenerative and anti-inflammatory properties and to promote functional recovery. Prior study also showed
etifoxine efficacy in reducing brain edema in rats. In light of these positive results, we used a rat model of TBI to
explore etifoxine treatment effects in a central nervous system injury, from functional outcomes to the
underlying mechanisms.
Methods: Male Sprague-Dawley rats received contusion (n = 18) or sham (n = 19) injuries centered laterally to
bregma over the left sensorimotor cortex. They were treated with etifoxine (50 mg/kg, i.p.) or its vehicle 30 min
following injury and every day during 7 days. Rats underwent behavioral testing to assess sensorimotor function.
In another experiment, injured rats (n = 10) or sham rats (n = 10) received etifoxine (EFX) (50 mg/kg, i.p.) or its
vehicle 30 min post-surgery. Brains were then dissected for analysis of neuroinflammation markers, glial
activation, and neuronal degeneration.
Results: Brain-injured rats exhibited significant sensorimotor function deficits compared to sham-injured rats in
the bilateral tactile adhesive removal test, the beam walking test, and the limb-use asymmetry test. After 2 days
of etifoxine treatment, behavioral impairments were significantly reduced. Etifoxine treatment reduced pro-
inflammatory cytokines levels without affecting anti-inflammatory cytokines levels in injured rats, reduced
macrophages and glial activation, and reduced neuronal degeneration.
Conclusions: Our results showed that post-injury treatment with etifoxine improved functional recovery and
reduced neuroinflammation in a rat model of TBI. These findings suggest that etifoxine may have a therapeutic
potential in the treatment of TBI.
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Background
Traumatic brain injury (TBI) is a leading cause of mortal-
ity and morbidity and can result in long-term physical, be-
havioral, and cognitive deficits. These deficits are due to
both primary and secondary injuries. The primary injury
occurs at the moment of TBI impact, with disruption of
blood brain barrier and blood vessels that contribute to
edema formation [1]. This primary injury precedes several
downstream events contributing to secondary injury cas-
cade of cellular, molecular, and metabolic pathological
events, such as activation of brain-resident microglia and
astrocytes, production of cytokines and chemokines, or re-
cruitment of peripheral immune cells into the brain [2–4].
TBI is also followed by a profound reorganization of the
GABAergic system and a dysregulation of the mitochon-
drial 18kDa translocator protein (TSPO) levels [5]. These
events may lead to acute and chronic cell death and con-
tribute to functional impairments [6, 7]. The onset of sec-
ondary injuries can be delayed for minutes to hours and
persist for weeks to months [8, 9].
Etifoxine (EFX) ((2-ethylamino-6-chloro-4-methyl-4-
phenyl-4H-3,1-benzoxazine hydrochloride) is an anxio-
lytic compound that belongs to the benzoxazine family.
Its anxiolytic and anticonvulsant properties have been
shown in rodents [10, 11], and it is effective in the treat-
ment of adjustment disorders with anxiety in humans
[12–14]. Etifoxine binds directly to the GABAA receptor,
acting as a positive allosteric modulator, thus potentiat-
ing GABAergic synaptic transmission [10, 15–17]. EFX
also activates TSPO [18] which plays an important role
for the synthesis of neurosteroids [19]. Etifoxine was in-
deed shown to inhibit the binding of the selective TSPO
ligand [3H]PK11195. In addition, i.p. administration of
EFX increased plasma and brain concentrations of pro-
gesterone, pregnenolone, 5α-dihydroprogesterone, and
allopregnanolone [18, 20]. The formation of these neu-
rosteroids might result in a brain region-specific en-
hancement of GABAergic neuronal inhibition [21]. In
the central nervous system (CNS), TSPO is generally
expressed in both microglia and in reactive astrocytes
[22]. Although TSPO level in the brain is low, it
increases after brain injury [5, 22] and is thus a marker
of brain injury and repair [5, 23–25]. Emerging evi-
dence suggests that administration of TSPO selective li-
gands may be a therapeutic tool in the treatment of
inflammatory conditions [26] and might be neuropro-
tective [27–29]. Some studies showed that EFX displays
potent regenerative and anti-inflammatory properties,
promotes functional recovery in experimental models
of traumatic peripheral nerve injury, and reduces brain
edema in rats [30–32]. To investigate further the poten-
tial neuroprotective and anti-inflammatory effect of
EFX, we tested this compound in a model of TBI in-
duced by controlled cortical impact (CCI) [33, 34] in
male adult rats. This model has numerous advantages
such as the possibility to control deformation parame-
ters, including duration, depth, and velocity of impact.
Methods
Animal subjects
All experiments were performed on male Sprague-
Dawley rats weighing 250–300 g at the time of injury
(Janvier laboratories, Le Genest Saint Isle, France).
Rats were group-housed with ad libitum access to food
and water in a temperature-controlled (22 ± 2 °C) and
humidity-controlled (55 ± 10 %) environment. Lights
were on a 12-h light/dark cycle (lights on at 7:00 a.m).
Experiments were carried out in strict accordance with
the European Community regulations for animal use in
research (2010/63/EU directive), and all protocols were
approved by the Local Ethical Committee (C2EAn°72).
Drugs
Etifoxine (batches 562 and 653, Biocodex, Gentilly,
France) was suspended in 0.9 % saline containing 1 %
Tween 80 (vol/vol). This compound and its vehicle were
administered intraperitoneally (i.p.) in a volume of
5 mL/kg of bodyweight.
Traumatic brain injury procedure
Rats were subjected to TBI using a controlled cortical
impactor (Impact One™, Leica Microsystem, Illinois,
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USA). Following deep anesthesia using isoflurane (induc-
tion 4 %, maintenance 2 %), rats were stabilized in a
stereotaxic frame (David Kopf Instruments, California,
USA) and placed on a heated pad. After exposing the
skull, a 4-mm diameter circular craniotomy was per-
formed using an electronic hand drill. Rats received con-
tusion injury centered 2 mm lateral to the bregma over
the left sensorimotor cortex with a velocity of 3.0 m/s, a
depth of 1.5 mm, and a duration of 0.5 s [34–38]. The
impactor tip was angled 8° vertically to maintain a per-
pendicular position in reference to the tangential plane
of the brain convexity at the impact surface. A small
quantity of saline solution at room temperature was di-
rected at the site of drilling to prevent thermal injury
[39]. After the impact, the scalp was sutured closed.
Sham animals received craniotomy but no impact from
the CCI device. All animals were closely monitored
post-operatively with weight and health surveillance.
Experimental design
This study was divided in two parts. In the first part, we
wanted to assess the effects of EFX treatment on sen-
sorimotor deficits induced by CCI in rats. To this aim,
we administered EFX at the anxiolytic-like effective dose
of 50 mg/kg, i.p. [10], or its vehicle, 30 min after TBI
(n = 10 for TBI-vehicle group, n = 8 for TBI-EFX group)
or sham surgery (n = 9 for sham-vehicle group, n = 10
for sham-EFX group), then daily after behavioral testing
during 1 week. The second part consisted in studying
the effects of EFX treatment on neuroinflammation
markers induced by TBI in our rat model (n = 5/group).
The critical time-points to study were chosen based on
the behavioral results.
Effects of EFX treatment on sensorimotor performances
Bilateral tactile adhesive removal test This test was
performed on days 2, 5, and 7 post-CCI in order to test
the forepaw sensitivity as well as motor impairments
[40–42]. Each rat was placed into a transparent box
(426 × 266 × 185 mm) during a habituation period of
60 s. Thereafter, two adhesive labels (13 mm diameter,
Tough-Spots®) were applied with equal pressure on each
animal’s wrist as bilateral tactile stimuli. The time to
contact each paw (“contact time”) and to remove (“re-
moval time”) the adhesive labels were measured with a
maximum of 120 s. The contact time is defined as the
time it takes for the rat to react to the presence of the
adhesive labels. The rat may either shake its paw and/or
bring it to its mouth. There were 5 days of pre-testing in
order to obtain an optimal level of performance, to limit
inter-individual variations and asymmetries. A trial ended
when the rat removed both labels or after 3 min.
Tapered beam walking test Motor performance and
coordination can be measured with the tapered beam
walking test [43]. Prior to surgery, all animals were
trained to traverse a 165-cm long elevated, tapering
beam with a 2-cm ledge in order to go in their home
cage (Campden Instruments, Lafayette, IN, USA) (two
trials per day for 5 days). Criterion performance was
assessed as the ability to traverse the beam five times in
a row without stopping. The day of the test (on days 2,
5, and 7 post-CCI), animals are videotaped while travers-
ing the beam (four trials), and performance was rated on
the percentage of contralateral hind limb faults (calcu-
lated by dividing the number of foot faults by the total
number of steps and multiplying by 100) [44, 45].
Limb-use asymmetry test This procedure was adapted
from Schallert et al. [46]. Injured animals use less often
their contralateral limbs (injured site) to balance them-
selves while rearing along the wall of the cylinder [47].
Each animal was placed in a transparent glass cylinder
(20 cm diameter and 38 cm height), and its spontaneous
activity to explore the vertical surface with its forelimbs
was analyzed by videotaping during 3 min. A mirror was
placed behind the cylinder at an angle to allow the ob-
server to record forelimb movements when the animal
was turned away from the camera. Rats used either both
forelimbs or a single one for an exploration. The number
of both, right only, or left only explorations was counted.
The laterality score was computed as follows: (number
of left only − number of right only)/(number of left
only + number of right only + number of both). Rats
with unilateral lesion prefer to use the limb ipsilateral
to the lesion.
Effects of EFX treatment on neuroinflammation
GFAP and CD68 immunostaining Forty-height hours
after surgery (24 h after the second and last EFX admin-
istration), animals were deeply anesthetized with sodium
pentobarbital (80 mg/kg) and perfused intracardially
with phosphate buffer saline (PBS) at room temperature
followed by ice-cold 4 % paraformaldehyde (PFA). Brains
were removed and post-fixed in the same fixative for
24 h and soaked in 30 % sucrose solutions. Brains were
then frozen and sectioned (50 μm) using a cryostat
(Leica CM 1850, Leica, Wetzlar, Germany). Free-floating
sections were immunostained for glial fibrillary acidic
protein (GFAP), a marker of astrocytic activation, and
cluster of differentiation 68 (CD68), a marker of macro-
phages and activated microglia, as follow: slides were
rinsed in tris-buffered saline (TBS, pH 7.4), then incu-
bated for 30 min with hydrogen peroxide to quench en-
dogenous peroxidases, rinsed in TBS-Triton (TBS-T),
and pre-incubated 60 min with 5 % blocking serum in
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TBS-T. Tissue sections were then incubated overnight
at 4 °C with a rabbit anti-GFAP antibody (Abcam,
Cambridge, UK) diluted (1:5000) or a mouse anti-CD68
antibody (Bio-Rad Laboratories, Hercules, CA, USA)
diluted (1:200) in TBS-T containing 2 % normal goat
serum (NGS). Slides were rinsed in TBS-T and incu-
bated 30 min with a goat anti-rabbit biotinylated anti-
body (Abcam) diluted (1:500) or a goat anti-mouse
biotinylated antibody (Abcam) diluted (1:500) in TBS-T
and 2 % NGS. Slides were then rinsed and processed by
using the Vectastain ABC Elite kit (Vector Laborator-
ies, Burlingame, CA, USA) and stained with diamino-
benzidine and hydrogen peroxide.
Fluoro-jade B staining Fluoro-jade B (FJB) is a fluores-
cent marker that sensitively and specifically binds to de-
generating neurons [48]. Brain sections were first
incubated in absolute ethanol during 3 min, then 70 %
ethanol during a minute, and rinsed in distilled water.
Sections were then incubated in a solution of 0.06 %
potassium permanganate for 15 min, rinsed in distilled
water for a minute, and incubated in 0.0004 % solution
of FJB (Interchim, Montluçon, France) for 30 min.
Image analysis Slices were mounted on coverslips with
Neo-Mount® mounting medium (VWR, Fontenay-sous-
Bois, France) before analysis with an optical microscope
(Leica DM 4000, Leica) coupled to a camera (Sony
XCD-U100CR, Sony, Tokyo, Japan) and to an acquisition
system (Archimed, Microvision Instruments, Evry, France).
All images were acquired using the same light level by
using a 20× (for CD68 and GFAP immunostaining) or 10×
(for FJB staining) objective lens. The number of CD68+
cells was counted manually: three sections from each rat
were selected for analysis. One section was at the epicenter
of the impact (bregma 0 mm) while the other two were ei-
ther 300 μm rostral or caudal to the epicenter. For GFAP
expression, 12 non-consecutive sections were immuno-
stained, representing the area of the lesion (approximately
bregma +1.8 mm to bregma −1.8 mm) and quantified. Sec-
tions were digitized as grayscale images after background
subtraction for quantification of intensity (Image J, NIH,
version 1.46). For FJB staining, all sections were observed
and photographed with blue excitation light (480 nm). The
number of FJB+ cells was counted manually in the contu-
sion margin along the cortex. For all analysis, brain sec-
tions from stereotaxically corresponding regions were
used in sham-treated rats.
Cytokine immunoassay Cytokine multiplex assay was
performed on the cerebral cortex. Brain tissues were
harvested and frozen 6 or 12 h post-injury separately
from each hemisphere. Tissues were then homogenized
in a lysis buffer (RIPA buffer, Abcam) containing
protease inhibitor cocktail (Pierce™ protease inhibitor,
Thermo Fisher Scientific, Waltham, MA, USA). Tissue
homogenates were centrifuged at 13,000 rpm for 20 min
at 4 °C. Supernatants were transferred to new tubes and
used for analysis. All assays were performed according
to the manufacturer’s instructions, in duplicates, and
without adjustments to the recommended standard
curve dilution. The concentration of 12 cytokines/che-
mokines (IL-1α, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-10,
IL-12, TNF-α, GM-CSF, MCP-1, and MIP-1α) was de-
terminate by Bio-Plex Pro™ rat cytokine assays (catalog
number: 171-K1001M, Bio-Rad Laboratories, Hercules,
CA, USA) in 500 μg of total protein of brain cortices ho-
mogenates (Bradford assay, Bio-Rad Laboratories). Briefly,
magnetic beads conjugated with cytokine antibodies were
loaded into the wells of a 96-well plate. After washing,
standards and samples were added into wells and incu-
bated for 60 min at room temperature on a shaking
platform. The beads were washed and incubated with
biotinylated detection antibody for 30 min at room
temperature. Following the removal of excessive detec-
tion antibodies, streptavidin-phycoerythrin conjugate
compound was added and allowed to incubate for
10 min at room temperature. Cytokines concentrations
were determined by Bio-Plex Manager™ MP software
version 6.1 and calculated against the standard curve.
Samples with out of range (low) levels were assigned
the limit of detection (LOD) (Table 1) of the assay for
analysis purposes. The intra-assay percentage coeffi-
cient of variation (CV) ranged from 1.28 to 9.48 %.
Statistical analysis All data are presented as mean ±
standard error of the mean (SEM) and were submitted
to a square root transformation to meet the require-
ments of normality if necessary. Behavioral data were
analyzed using three two-way analysis of variance
Table 1 Limit of detection (LOD) of the Bio-Plex Pro™ rat cytokine
assays (Bio-Rad Laboratories, Hercules, CA, USA)
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(ANOVA) with repeated measures (RM) with post hoc
Tukey’s multiple comparison test. The first ANOVA
consists in studying the effects of TBI on sensorimotor
performances (comparison between sham-vehicle and
TBI-vehicle groups) with two factors: time in RM and
injury. Then, we did the same type of analysis for the
effects of EFX treatment on the TBI group and on the
sham-operated one. Significant main or interaction ef-
fects were followed by Tukey post hoc analyses. Bio-
chemical data were analyzed using a two-way ANOVA
(TBI or Sham) x (EFX or Vehicle) with post hoc
Tukey’s multiple comparison test. Inflammatory load
score (ILS) was calculated for each rats as follow: ani-
mals with the lowest values for a given cytokine (≤25th
percentile) were assigned a 1, between the 26th and
the 50th percentile animals were assigned a 2, between
the 51th percentile and the 75th percentile animals
were assigned a 3, and for the largest values (≥76th
percentile), animals were assigned a 4. An ILS for each
rat was calculated by summing the quartile rank for
each of the pro-inflammatory cytokines. All statistical
analyses were performed using SigmaStat® software v
3.5 (Systat Software Inc., San Jose, California, USA).
Significance was set at p < .05.
Results
Etifoxine improves adhesive removal task at 2 days
post-CCI
Results showed that before surgery, all groups of rats felt
the presence of the adhesive stuck on their wrists very
quickly (less than 1 s for each animal). Statistical ana-
lyses (two-way RM ANOVA) revealed no significant ef-
fect of the injury factor (F1, 18 = 3.718, p = 0.071), a
significant effect of time (F3, 54 = 10.873, p < 0.001) and
a significant interaction (F3, 54 = 3.441, p = 0.023). Post
hoc analyses showed that 2 days post-surgery, TBI-
vehicle-treated rats needed significantly more time to
feel the presence of the adhesive compared to pre-
surgery (53.3 ± 16.5 s) (p < 0,001). Sham-operated ani-
mals did not present any deficit. In the injured group,
two-way RM ANOVA showed no effect of treatment
(F1, 16 = 2.208, p = 0.157), a significant effect of time
(F3, 48 = 12.826, p < 0.001) and no significant inter-
action (F3, 48 = 1.954, p = 0.133). Post hoc analyses
showed that EFX treatment significantly reduced the
contact time in injured animals 2 days post-surgery
(23.7 ± 9.7 s vs. 53.3 ± 16.5 s, p = 0.006). No significant
differences were observed on day + 5 and day + 7 post-
surgery in any groups (Fig. 1).
Fig. 1 Bilateral adhesive removal test. Mean (+SEM) time to contact the contralateral adhesive in sham-vehicle (n = 9), TBI-vehicle (n = 10), sham-
EFX (n = 10), and TBI-EFX (n = 8) groups. EFX treatment significantly improved the time to contact on day 2 post-CCI compared with vehicle treatment
in TBI animals (##p < 0.01). ***p < 0.001 compared to pre-TBI; ###p < 0.001 and ##p < 0.01 compared to TBI-vehicle
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Mean removal time was 16.72 ± 1.85 s in all groups be-
fore surgery. Two-way RM ANOVA revealed a main ef-
fect of injury (F1, 18 = 6.150, p = 0.024), a main effect of
time (F3, 54 = 10.747, p < 0.001) and no significant inter-
action (F3, 54 = 2.602, p = 0.062). Post hoc Tukey’s ana-
lyses revealed that injured-vehicle-treated animals spent
significantly more time to remove the adhesive than
sham-vehicle-treated animals at day 2 post-surgery
(83.4 ± 16.2 s vs. 35.9 ± 12.6 s, p < 0.001). Two-way RM
ANOVA showed no significant treatment effect in the
injured group (F1, 16 = 2.744, p = 0.117) but a significant
effect of time (F3, 48 = 14.258, p < 0.001) and no signifi-
cant interaction (F3, 48 = 1.035, p = 0.386). Post hoc ana-
lyses showed that treatment with EFX significantly
reduced the time to remove the adhesive in injured ani-
mals (52.6 ± 12.9 s vs. 83.4 ± 13.2 s, p = 0.043). No sig-
nificant differences were observed on day + 5 and day +
7 post-surgery in any groups (Fig. 2).
Etifoxine improves beam walk task at 2 days post-CCI
Two-way repeated measures ANOVA revealed that ex-
posure to CCI injury resulted in a main significant effect
(F1, 18 = 10.014, p = 0.005), a significant main effect of
time (F3, 54 = 10.624, p < 0.001) and a significant inter-
action (F3, 54 = 9.084, p < 0.001). Post hoc analyses
showed that 2 days post-injury, TBI-vehicle-treated
animals made more foot faults in comparison with
sham-vehicle animals (39.8 ± 8.9 vs. 4.7 ± 2.5 %, p <
0.001). At day + 5 and day + 7 post-surgery, this impair-
ment is not observed anymore. In the injured groups,
two-way RM ANOVA showed no effect of treatment (F1,
16 = 1.296, p = 0.272), a significant main effect of time
(F3, 48 = 14.666, p < 0.001) and no significant interaction
(F3, 48 = 1.217, p = 0.314). Post hoc analyses showed that
two days of EFX treatment significantly reduced the per-
centage of contralateral hind limb faults in TBI-EFX ani-
mals in comparison with TBI-vehicle-treated animals
(25.3 ± 9.2 vs. 39.8 ± 8.9 %, p = 0.039) (Fig. 3).
Etifoxine improves limb-use asymmetry test at 2 days
post-CCI
Two-way ANOVA with repeated measures showed a sig-
nificant effect of injury on rats (F1, 18 = 37.255, p < 0.001),
a significant effect of time (F3, 54 = 17.433, p < 0.001) and a
significant interaction (F3, 54 = 15.953, p < 0.001). Post hoc
analyses indicated that injured-vehicle-treated rats had
higher asymmetry scores at day + 2, day + 5, and day + 7
post-injury compared with sham-vehicle-treated animals
(p < 0.001). Two-way RM ANOVA showed a significant
main effect of EFX treatment in injured rats (F1, 16 =
7.203, p = 0.016), a significant effect of time (F3, 48 =
25.754, p < 0.001) and a significant interaction (F3, 48 =
Fig. 2 Bilateral adhesive removal test. Mean (+SEM) time to remove the contralateral adhesive in sham-vehicle (n = 9), TBI-vehicle (n = 10), sham-
EFX (n = 10), and TBI-EFX (n = 8) groups. EFX treatment significantly improved the time to remove the adhesive on day 2 post-CCI compared with
vehicle treatment in TBI animals (#p < 0.05). ***p < 0.001 and *p < 0.05 compared to pre-TBI; ###p < 0.001 and #p < 0.05 compared to TBI-vehicle
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3.280, p = 0.030). Tukey’s test showed a significant im-
provement in limb-use asymmetries in EFX-treated
animals compared to vehicle-treated animals 2 days
post-injury (p = 0.003) and 5 days post-injury (p =
0.017) (Fig. 4).
Etifoxine decreases astrogliosis in the injured cortex at
2 days post-CCI
Activated astrocytes were visualized by immunohisto-
chemistry for GFAP. Two-way ANOVA showed a sig-
nificant main effect of CCI (F1, 223 = 119.61, p < 0.001), a
Fig. 3 Tapered beam walking test. Mean (+SEM) percentage of faults with the contralateral hind limb on the beam in sham-vehicle (n = 9), TBI-
vehicle (n = 10), sham-EFX (n = 10), and TBI-EFX (n = 8) groups. Treatment with EFX significantly improved motor performance and coordination
on day 2 post-CCI compared to vehicle treatment in TBI animals (#p < 0.05). ***p < 0.001 compared to pre-TBI; ###p < 0.001 and #p < 0.05 compared
to TBI-vehicle
Fig. 4 Limb-use asymmetry test. Mean (+SEM) asymmetry score in sham-vehicle (n = 9), TBI-vehicle (n = 10), sham-EFX (n = 10), and TBI-EFX
(n = 8) groups. Higher scores indicate a greater use of the unimpaired forelimb. Treatment with EFX significantly improved asymmetry score
on day 2 (##p < 0.01) and day 5 (#p < 0.05) post-CCI compared to vehicle treatment in TBI animals. ***p < 0.001 and **p < 0.01 compared to
pre-TBI; ###p < 0.001, ## p < 0.01, and #p < 0.05 compared to TBI-vehicle
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significant main effect of EFX treatment (F1, 223 = 21.34,
p < 0.001), and no interaction (F1, 223 = 0.035, p = 0.851).
Post hoc Tukey’s analyses showed that immunostaining
for GFAP revealed evidence of a reactive astrogliosis in
regions of the cortex underlying the impact site at day +
2 post-surgery (21.3 ± 1.6 % in the TBI-vehicle group vs.
6.8 ± 1.2 % in the sham-vehicle group, p < 0.001). EFX
treatment significantly reduced GFAP immunoreactivity
in injured animals (15.0 ± 1.3 % in the TBI-EFX group
vs. 21.3 ± 1.6 % in the TBI-vehicle group, p = 0.001) as
well as in sham animals (1.1 ± 0.3 % in the sham-EFX
group vs. 6.8 ± 1.2 % in the sham-vehicle group, p =
0.001) (Fig. 5). Figure 5 shows the typical star-like
hypertrophied aspect of astrocytes in response to injury
which is a characteristic marker of the inflammatory
cascade induced by CNS trauma and which contributes
to later pathology.
Etifoxine reduces activated microglia/macrophage density
in the injured cortex at 2 days post-CCI
Blood-borne and resident macrophages/activated micro-
glia can be visualized by anti-CD68 staining (Fig. 6).
Two-way ANOVA revealed a significant main effect of
surgery (F1, 65 = 24.87, p < 0.001), a significant main ef-
fect of EFX treatment (F1, 65 = 13.09, p < 0.001), and no
interaction (F1, 65 = 1.099; p = 0.298). As shown in Fig. 6,
post hoc analyses showed a significant increase in CD68
+ cells in the cortical contusion margin of rats 2 days
post-CCI (584 ± 100 for TBI-vehicle group vs. 194 ± 61
for sham-vehicle group, p < 0.001). A significant reduc-
tion in the density of activated microglia/macrophages
was observed in EFX-treated rats compared with ve-
hicle controls (282 ± 33 in the TBI-EFX group vs. 584 ±
100 in the TBI-vehicle group, p < 0.001). No positive
staining was observed in the hemisphere contralateral
to the impact site.
Etifoxine reduces neuronal degeneration in the injured
cortex at 2 days post-CCI
Statistical analyses revealed a significant main effect of
surgery (F1, 297 = 51.439, p < 0.001), a significant main ef-
fect of EFX treatment (F1, 297 = 20.042, p < 0.001), and a
significant interaction (F1, 297 = 10.521, p = 0.001). Post
hoc analyses showed that FJB+ cells with neuronal
Fig. 5 Effect of EFX treatment on CCI-induced astrogliosis in rats 2 days post-injury. EFX (50 mg/kg, i.p.) or its vehicle were administered 30 min after
surgery and 24 h after (n = 5/group). Astrogliosis was evaluated with GFAP immunostaining. TBI induced an increase in GFAP immunoreactivity in the
ipsilateral side of the injury (p < 0.001). EFX treatment significantly reduced astrogliosis (p < 0.01) in injured animals in comparison with vehicle
treatment. Images show representative sections from each group (ipsilateral and contralateral side). Data are mean + SEM. @@@p < 0.001: comparison
between sham-vehicle and sham-EFX groups; ###p < 0.001: comparison between sham-vehicle and TBI-vehicle groups; **p < 0.01: comparison between
TBI-vehicle and TBI-EFX groups
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morphology were evident 2 days after CCI in the cortical
contusion margin but not in the contralateral hemi-
sphere. Ipsilateral minus contralateral FJB+ cells count-
ing showed that neuronal degeneration was significantly
more important in TBI-vehicle group compared with
sham-vehicle group (98 ± 11 for TBI-vehicle group vs. 8
± 3 for sham-vehicle group, p < 0.001). Etifoxine treat-
ment significantly reduced the number of FJB+ cells in
CCI rats compared with vehicle treatment (26 ± 5 for
TBI-EFX group vs. 98 ± 11 for TBI-vehicle group, p <
0.001) (Fig. 7).
Etifoxine reduces cortical level of pro-inflammatory
cytokines
Different studies showed that the temporal change of
several inflammatory cytokines peaked at 6 h after CCI
[3, 49]. We therefore selected this time-point for evalu-
ating EFX treatment on cytokine/chemokine expression.
There are no differences within contralateral sites of in-
jury between groups. Two-way ANOVA revealed statis-
tical differences for four pro-inflammatory cytokines,
IL-1α, IL-1β, IL-6, and TNF-α, and two chemokines:
MCP-1 and MIP-1α. Post hoc testing showed that there
was a significant increase in IL-1α, IL-1β, IL-6, TNF-α,
MCP-1, and MIP-1α levels in the ipsilateral cortices to
the injury site of TBI-vehicle-treated group in compari-
son with sham-vehicle-treated animals (p < 0.001). Statis-
tical analyses also showed that EFX treatment significantly
reduced this increase in pro-inflammatory cytokines and
chemokines levels in the injured group compared to ve-
hicle treatment (p < 0.001 for IL-1α, IL-1β, IL-6, and TNF-
α, p < 0.05 for MCP-1 and MIP-1α). Data are summarized
in Table 2. Because multiple testing across the analytes
may not be fully accounted for by multiple test correction
within each analyte, resulting in type I errors, we have also
performed an inflammatory load score (ILS) analysis
(Table 3). Two-way ANOVA revealed an overall effect of
TBI on inflammation (F1,15 = 15.46, p = 0.001), an overall
effect of EFX treatment (F1, 15 = 11.50, p = 0.004) on ILS,
and no interaction (F1, 15 = 3.584, p = 0.078). Post hoc ana-
lysis showed that injured animals have a higher ILS com-
pared to sham animals (p < 0.001) and that EFX treatment
significantly reduced ILS in injured animals (p = 0.003)
(see Table 3). We also tested the levels of pro-
inflammatory cytokines IL-1α, IL-1β, IL-6, and TNF-α
12 h after surgery in order to study their evolution of
Fig. 6 Effect of EFX treatment on CCI-induced microglia/macrophage activation in rats 2 days post-injury. EFX (50 mg/kg, i.p.) or its vehicle were
administered 30 min after surgery and 24 h after (n = 5/group). Microglia/macrophage activation was evaluated with CD68 immunostaining. TBI
induced an increase in CD68 immunoreactivity in the ipsilateral side of the injury (p < 0.001). EFX treatment significantly reduced microglia/
macrophage activation (p < 0.001) in injured animals in comparison with vehicle treatment. Images show representative sections from each
group (ipsilateral and contralateral side). Data are mean + SEM. ###p < 0.001: comparison between sham-vehicle and TBI-vehicle groups; ***p < 0.001:
comparison between TBI-vehicle and TBI-EFX groups
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expression. At 6 h time-point, the profound increase in
pro-inflammatory cytokines associated with trauma was
significantly reduced by EFX treatment (p < 0.001) com-
pared with vehicle-treated rats to such an extent that these
values were not different from those for the 12 h time-
point (Fig. 8). We did not find any modifications of other
tested cytokines in injured animals compared to sham ani-
mals (data not shown).
Discussion
Our results showed that TBI model induced by CCI
caused sensorimotor deficits in rats measured in three
behavioral tasks: bilateral adhesive removal test, tapered
beam walk test, and limb-use asymmetry test. An ad-
ministration of EFX 30 min after the injury, followed by
a second injection after 24 h, significantly improved
functional impairments. This protective effect was asso-
ciated with reduced neuroinflammation, astrogliosis, and
neuronal degeneration.
Following TBI, there is a wide range of cellular and
biochemical pathological events resulting in neuron and
glial cells death. Among these events, neuroinflamma-
tion is characterized by the activation of resident
astrocytes and microglia and by the infiltration of leuko-
cytes into the injury site. These events lead to the release
of inflammatory cytokines and neurotoxic molecules
which contribute to progressive cell death and functional
impairments [50].
Our results suggest that EFX may reduce delayed
neuronal death that contributes to neurological deficits
[51] and promote survival in the injury border zone.
This hypothesis is supported by the observations that
EFX-treated animals showed fewer degenerative neurons
than vehicle-treated rats as evaluated by FJB staining.
Among the different mechanisms underlying delayed
neuronal loss, post-traumatic neuroinflammation is a
major factor. Activation of microglia is one of the central
inflammatory responses after TBI [52]. Recent studies
showed that brain inflammation has been associated
with polarization of microglia and macrophages (M1
and M2 responses) [53–56]. M1 response is an activa-
tion of microglia/macrophages that produces pro-
inflammatory substances such as IL-1β, IL-6, and TNF-α
[56]. The M2 response is induced by anti-inflammatory
cytokines such as IL-4 and IL-10 [53]. Inflammation is
therefore an important tool for controlling TBI effects
Fig. 7 Effect of EFX treatment on CCI-induced neuronal degeneration in rats 2 days post-injury. EFX (50 mg/kg, i.p.) or its vehicle were administered
30 min after surgery and 24 h after (n = 5/group). Neuronal degeneration was evaluated with fluoro-jade B (FJB) staining. TBI induced an increase in
FJB staining in the ipsilateral side of the injury (p < 0.001). EFX treatment significantly reduced neuronal degeneration (p < 0.001) in injured animals in
comparison with vehicle treatment. Images show representative sections from each group (ipsilateral and contralateral side). Data are mean + SEM.
###p < 0.001: comparison between sham-vehicle and TBI-vehicle groups; ***p < 0.001: comparison between TBI-vehicle and TBI-EFX groups
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and enhancing recovery after injury. Thus, the suppres-
sion of M1 and/or the up-regulation of M2 response
could be used to prevent secondary injury and promote
repair processes in the brain. In a study using male
Sprague-Dawley rats, Ansari showed an upregulation of
pro-inflammatory cytokines (TNF-α, IL-1β, and IL-6)
expression 6 h post-CCI and an upregulation of anti-
inflammatory cytokines such as IL-4 and IL-10 but only
24 h post-injury [57]. These results support other studies
showing that early after injury, M1 predominate over
M2 response [54, 58, 59]. These observations are in ac-
cordance with our results showing an upregulation of
pro-inflammatory cytokines such as TNF-α, IL-1α, IL-
1β, and IL-6 early after injury but no upregulation of
anti-inflammatory cytokines such as IL-4 and IL-10 6 h
post-injury. Pro-inflammatory cytokines secreted by acti-
vated microglia also secrete chemokines that recruit
additional inflammatory cells to the injury site and free
radicals that are cytotoxic to neurons and can contrib-
ute to neurodegeneration after TBI [60, 61]. Elevated
levels of pro-inflammatory cytokines have been de-
tected in the serum and cerebrospinal fluid of TBI pa-
tients [62, 63] and in brain parenchyma of animals with
experimental brain injuries [64–67]. The role of these
pro-inflammatory cytokines has remained controversial,
but several studies showed that suppressing their ex-
pression may reduce tissue damage and brain edema
and also improve functional consequences [2, 68–78].
We demonstrated that acute administration of EFX sig-
nificantly reduced TBI-induced up-regulation of pro-
inflammatory cytokines. Since TNF-α, IL-1β, and IL-6
are major pro-inflammatory cytokines that mediate
blood brain barrier disruption, edema, and programmed
cell death resulting in loss of neurons [3, 71, 79–83], we
Table 2 Concentrations of cytokines/chemokines in the injured cortex at 6 h post-CCI or sham-operation in rats treated with EFX or
Vehicle control
Sham-vehicle (pg/mL) Sham-EFX (pg/mL) TBI-vehicle (pg/mL) TBI-EFX (pg/mL) TBI-vehicle vs.
TBI-EFX
Ipsilateral Contralateral Ipsilateral Contralateral Ipsilateral Contralateral Ipsilateral Contralateral % decrease
(ipsilateral side)
Pro-inflammatory cytokines
IL-1α 5.75 ± 0.87 5.17 ± 0.22 5.53 ± 0.81 3.83 ± 0.88 40.41 ± 5.14*** 3.27 ± 0.63 13.55 ± 2.65** 1.32 ± 0.77 33
IL-1β 45.14 ± 2.89 37.68 ± 2.43 56.58 ± 9.43 34.77 ± 3.25 382.88 ± 64.66*** 33.98 ± 1.57 148.97 ± 25.50** 29.82 ± 1.72 39
IL-2 26.47 ± 0.75 24.84 ± 0.70 23.48 ± 0.50 22.89 ± 1.57 27.55 ± 4.42 21.55 ± 0.62 23.44 ± 1.64 20.46 ± 0.64 ns
IL-6 2.65 ± 0.33 1.76 ± 0.23 14.00 ± 8.89 3.21 ± 0.71 150.18 ± 21.25*** 4.34 ± 0.64 41.97 ± 10.25** 1.86 ± 0.51 28
IL-12 8.87 ± 0.29 8.54 ± 0.38 7.50 ± 0.24 7.50 ± 0.95 7.41 ± 0.26 6.95 ± 0.38 6.95 ± 0.20 7.10 ± 0.20 ns
TNF-α 5.34 ± 0.35 1.30 ± 0.14 5.93 ± 0.36 4.48 ± 0.84 16.34 ± 1.71*** 5.24 ± 0.62 9.91 ± 1.28** 5.91 ± 0.70 60
GM-CSF 2.49 ± 0.67 2.24 ± 0.49 2.06 ± 0.26 1.52 ± 0.29 1.20 ± 0.22 1.15 ± 0.17 1.07 ± 0.27 1.36 ± 0.14 ns
Anti-inflammatory cytokines
IL-4 2.86 ± 0.13 2.50 ± 0.08 3.20 ± 0.53 2.85 ± 0.51 4.19 ± 0.78 2.54 ± 0.05 3.65 ± 0.72 2.32 ± 0.13 ns
IL-5 11.22 ± 0.24 10.74 ± 0.24 7.93 ± 0.31 6.72 ± 1.71 9.34 ± 0.63 9.24 ± 0.89 9.30 ± 1.18 9.00 ± 1.13 ns
IL-10 25.99 ± 1.60 24.13 ± 1.67 19.94 ± 2.04 19.66 ± 4.35 35.29 ± 4.98 17.52 ± 2.82 28.48 ± 2.45 23.12 ± 0.83 ns
Macrophage-attracting chemokines
MIP-1α 1.71 ± 1.01 0.04 ± 0.04 2.64 ± 1.3 0.00 ± 0.00 90.42 ± 25.47*** 0.00 ± 0.00 36.99 ± 4.51* 0.24 ± 0.21 41
MCP-1 7.50 ± 1.97 4.30 ± 0.63 12.82 ± 5.16 4.25 ± 0.64 93.82 ± 21.66*** 5.53 ± 0.97 53.00 ± 7.45* 6.34 ± 1.55 56
Six hours post TBI, ipsilateral and contralateral cortices were analyzed with the Bio-Plex Pro™ rat cytokine assays for IL-1α, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12,
TNF-α, GM-CSF, MIP-1α, and MCP-1
Data (n = 5/groups) represents mean ± SEM. p < 0.05 or less were considered statistically significant. Two-way analysis of variance was performed, followed by
Tukey post hoc test
NS not significant
***p < 0.001: comparison between sham-vehicle and TBI-vehicle groups in the ipsilateral side; **p < 0.001 and *p < 0.05: comparison between TBI-vehicle and TBI-
EFX groups in the ipsilateral side
Table 3 Inflammatory load score (ILS) of each group of rats (sham-vehicle, sham-EFX, TBI-vehicle, TBI-EFX, n = 5/groups) measured in
the ipsilateral side of the lesion 6 hours post TBI
Sham TBI
Vehicle EFX p value Vehicle EFX p value
Mean ILS (SEM) 2.371 (0.21) 2.114 (0.15) 0.292 3.371 (0.15) 2.464 (0.16) 0.003
Ipsilateral cortices were analyzed with the Bio-Plex Pro™ rat cytokine assays. The cytokines used for the score were IL-1α, IL-1β, IL-2, IL-6, IL-12, TNF-α, and GM-CSF.
Data represents mean (SEM)
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can hypothesized that EFX may exerts its neuroprotective
actions, at least in part, by suppressing the expression of
these cytokines which are detrimental in the acute post-
traumatic period.
Experimental and clinical data show that GFAP and
other intermediate filaments such as nestin and vimentin
are considerably upregulated following TBI [84–86]. In
our study, 2 days after TBI, there was a significant in-
crease in GFAP immunoreactivity in the perimeter of
the cortical lesion and in the subcortical white matter,
reflecting increased astrocytic activation in the cortex
ipsilateral to the injury site. This observation is in ac-
cordance with other studies [64, 85]. Two days of EFX
treatment significantly reduced this astrocytic activa-
tion. This is important to note because astrocytic acti-
vation increases the production of pro-inflammatory
cytokines, reactive oxygen species, excitatory amino
acids, and nitrogen oxides and can also induce blood
brain barrier disruptions that induce immune cell infil-
tration [87–89]. GFAP also promotes scarring and glial
proliferation which is deleterious on neuronal regener-
ation and recuperation [90].
Our results are in accordance with other studies that
show that TSPO ligands exert neuroprotective effects
and reduce neural inflammation [26, 28–30]. Girard et
al. indeed showed that EFX treatment decreased mes-
senger RNA (mRNA) expression of pro-inflammatory
cytokines TNF-α, Il-1β, and IL-6 and improved func-
tional recovery in a model of peripheral nerve injury in
rats and also had beneficial effects on axonal regrowth
and on macrophage response [30, 32]. Ravikumar et al.
showed that EFX treatment reduced lipopolysaccharide
(LPS)-induced IL-1β and IL-6 release from rat primary
astrocytes in a concentration-dependent manner [91].
Daugherty et al. also showed a decrease in pro-
inflammatory cytokines after EFX treatment in a model
of multiple sclerosis [92].
Etifoxine, which is a TSPO ligand, has been shown to
be a potent enhancer of neurosteroidogenesis and to
induce the synthesis of pregnenolone, progesterone,
and allopregnanolone [18, 20, 93] which have demon-
strated neuroprotective properties. Progesterone treat-
ment following TBI in rats has indeed been
demonstrated to reduce cerebral edema, cell death me-
diators expression, inflammatory response, reactive
gliosis, and necrosis and to improve functional recovery
[94–100]. In their studies, He at al. [8, 101] demon-
strated that allopregnanolone significantly reduced
Fig. 8 Cortical cytokine levels at 6 and 12 h post-CCI. The pro-inflammatory cytokines IL-1α, IL-1β, Il-6, and TNF-α were significantly elevated 6 h
after CCI in the injury and margin regions compared to sham animals (***p < 0.001 for all groups). Statistical analyses showed no difference at
12-h time-point. Six hours after CCI, EFX treatment (50 mg/kg, i.p., 30 min after injury) significantly reduced IL-1α, IL-1β, IL-6, and TNF-α peaks
(###p < 0.001 for all groups). ***p < 0.001: comparison between sham-vehicle and TBI-vehicle groups; ###p < 0.001: comparison between TBI-
vehicle and TBI-EFX groups
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neuronal loss and enhanced cognitive and behavioral
recovery in a model of TBI in rats. These results sug-
gest that EFX, a TSPO ligand, may protect neuronal
function by inducing neurosteroids biosynthesis.
In addition to its action on TSPO receptor, EFX exerts
a direct effect on GABAA receptor as a positive allosteric
modulator [10]. This is of interest because a significant
decrease in inhibitory synaptic transmission has been
shown in the basolateral amygdala of rats subjected to
CCI, associated with a decrease of surface expression
of GABAA receptors [102]. Furthermore, glutamatergic
projections from the mediodorsal thalamic nucleus and
cholinergic projections from the nucleus basalis mag-
nocellularis to the prefrontal cortex are known to be
modulated by GABA transmission [103, 104] and are
highly sensitive to TBI [8, 94]. Excessive release of glu-
tamate and acetylcholine following TBI causes excito-
toxicity that could thus be prevented by direct action
of EFX on inhibitory GABAA receptors and its indirect
action on the synthesis of allopregnanolone, which also
potentiate GABA transmission [105, 106].
Conclusions
EFX treatment after TBI considerably improves func-
tional outcomes. This effect is associated with reductions
in neuronal degeneration, in glial scar formation and in
microglial activation. Neuroinflammation is a major sec-
ondary injury mechanism that provides later neurode-
generation and neurologic impairments associated with
TBI. We can hypothesize that functional and histological
improvement of EFX-treated animals is due to its modu-
lation of early inflammation mechanisms. These results
are interesting because pre-clinical studies which com-
bine both neurobehavioral and histological evaluations
may improve the predictive value of animal models for
clinical efficacy with novel neuroprotective agent [50]. In
addition, the beneficial neuroprotective effects of EFX at
an earliest stage of TBI might attenuate other deleterious
effects such as anxiety disorders and memory distur-
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